The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Minimal Residual Disease Market During The Forecast Period 2026–2030?
The minimal residual disease market has experienced rapid expansion in recent years. It is anticipated to grow from $2.01 billion in 2025 to $2.26 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.5%. This market’s historical growth can be attributed to several factors, including a rise in leukemia and lymphoma cases, the increasing utilization of flow cytometry testing, the early adoption of pcr-based mrd detection, a growing clinical focus on relapse prediction, and the expansion of diagnostic laboratory capabilities.
The minimal residual disease market is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $3.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. Factors driving this growth during the projected period include the accelerated adoption of NGS-based MRD testing, a rising need for individualized oncology therapies, the creation of highly sensitive molecular assays, broader acceptance of liquid biopsy MRD testing, and increased funding for cancer diagnostics research. Key trends expected during this forecast timeframe encompass the implementation of precision medicine in MRD detection, the incorporation of AI to boost sensitivity in MRD testing, an increase in cloud-based data management solutions for MRD monitoring, IoT-enabled connectivity within MRD diagnostic platforms, and the progression of automation and digitalization in laboratory MRD analysis.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp
Which Major Factors Are Driving The Expansion Of The Minimal Residual Disease Market?
The expanding occurrence of cancer is anticipated to drive the advancement of the minimal residual disease market moving ahead. Cancer refers to a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body. This growing incidence of cancer stems from various elements, including an older demographic, greater contact with environmental cancer-causing agents, detrimental daily habits, and inherited susceptibilities. This escalating cancer rate fuels the need for accurate minimal residual disease testing to identify remaining cancer cells, allowing for prompt intervention and tailored therapies. Such testing improves the foresight of relapse and boosts patient recovery. For example, data from February 2024, provided by the World Health Organization, an intergovernmental entity based in Switzerland, indicated that by 2050, more than 35 million new instances of cancer are predicted, signifying a 77% surge from the approximate 20 million cases recorded in 2022. Consequently, the rising occurrence of cancer is a key factor propelling the expansion of the minimal residual disease market.
What Market Segments Are Evaluated Within The Minimal Residual Disease Market?
The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions
Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
What Trends Are Advancing Progress In The Minimal Residual Disease Market?
Leading companies operating within the minimal residual disease (MRD) market are concentrating on developing advanced ultra-sensitive assays to enhance both early detection and patient management. These ultra-sensitive assays are laboratory tests specifically designed to detect circulating tumor DNA at extremely low frequencies with high accuracy, enabling an earlier identification of cancer recurrence and improved treatment decisions. For instance, in April 2025, Natera, Inc., a US-based provider of cell-free DNA and genetic testing services, launched the Signatera Genome MRD test, which features a personalized, tumor-informed assay constructed from a patient’s whole genome sequence and matched normal DNA. The test employs multiplex polymerase chain reaction and next-generation sequencing technology to detect tumor DNA at frequencies as low as 1 part per million and even below for research use. It has undergone clinical validation across numerous cancer types, including breast, colorectal, non-small cell lung, melanoma, and renal cell carcinoma. Signatera Genome is capable of identifying postsurgical patients who are at a higher risk of recurrence, offers predictive clinical utility, supports both clinical and research applications, and benefits from Medicare coverage across a broad spectrum of indications, thereby enabling more precise and informed treatment strategies.
Who Are The Top Market Participants Influencing The Minimal Residual Disease Market?
Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., LabCorp, Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Illumina Inc., Personalis Inc., Asuragen Inc., ARUP Laboratories Inc., Myriad Genetics Inc., Luminex Corporation, EntroGen Inc., 3B BlackBio Biotech India, Bioartis, PerkinElmer Inc.
Read the full minimal residual disease market report here:
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report
Which Region Currently Holds The Largest Share Of The Minimal Residual Disease Market?
North America was the largest region in the minimal residual disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Minimal Residual Disease Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21224&type=smp
Browse Through More Reports Similar to the Global Minimal Residual Disease Market 2026, By The Business Research Company
Mineral Oil Global Market Report
https://www.thebusinessresearchcompany.com/report/mineral-oil-global-market-report
Mineral Supplements Global Market Report
https://www.thebusinessresearchcompany.com/report/mineral-supplements-global-market-report
Mineral Global Market Report
https://www.thebusinessresearchcompany.com/report/mineral-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model